Sou FM, Chen CH, Huang PY, Tsai MC, Yen YH, Lu SN, Hung CH, Kuo YH*. Strategies of hepatitis C virus elimination for people who inject drugs receiving opioid agonist therapy in the era of direct-acting antivirals. Adv Dig Med. 2024;11:189–195. 在直接作用抗病毒藥物時代，接受鴉片類替代物治療的藥物成癮患者的C型肝炎病毒消除策略
Sou FM, Hsu CN, Chiu YC, Wu CK, Lu LS, Kuo CM, Chiu SM, Chuah SK, Yang YH, Liang CM*. The association between trajectory of serum cholesterol, statin dosage, and the risk of recurrent biliary stone diseases. J Formos Med Assoc. 2024 Apr 7:S0929-6646(24)00203-1. (SCI) 從血中膽固醇的軌跡變化和它汀藥物使用劑量來探討膽管結石疾病復發之相關性
Sou FM, Hu TH, Hung CH, Lai HC, Wang JH, Lu SN, Peng CY*, Chen CH*. Incidence and predictors of hepatocellular carcinoma beyond year 5 of entecavir therapy in chronic hepatitis B patients. Hepatol Int. 2020 Jul;14(4):513-520. (SCI) 慢性B型肝炎病患接受貝樂克治療5年後發生肝癌的機率和預測因子
Sou FM, Wu CK, Chang KC, Lu SN, Wang JH, Hung CH, Chen CH, Kee KM, Yen YH, Lin MT, Tsai MC, Hu TH*.Clinical characteristics and prognosis of HCC occurrence after antiviral therapy for HCV patients between sustained and non-sustained responders. J Formos Med Assoc. 2019 Jan;118(1 Pt 3):504-513. (SCI) C型肝炎經干擾素治療後發生肝癌的特徵與預後之比較
